Genflow Biosciences Plc (GB:GENF) has released an update.
Genflow Biosciences Plc, a biotech firm at the forefront of longevity research, has announced its total voting rights, with 349,706,618 Ordinary Shares in circulation, none held in treasury. Shareholders can use this figure as a denominator for declaring changes in their shareholdings as per regulatory guidelines. The company’s pioneering gene therapy, GF-1002, targeting age-related diseases, is set to begin clinical trials in 2025 to address the unmet medical need in NASH treatment.
For further insights into GB:GENF stock, check out TipRanks’ Stock Analysis page.
